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See Article, pages 820–827Drug-induced liver injury (DILI) is a leading cause of acute liver
failure [1] and is of major importance to the pharmaceutical
industry, as it is the most frequent reason for withdrawal of sub-
stances from the market. More than 1000 different drugs and her-
bal remedies have been described to cause DILI. Some drugs
cause a dose-dependent toxicity which can be anticipated – a
well known example is acetaminophen. The vast majority of DILI
cases cannot be foreseen and are, therefore, termed idiosyncratic.
Oxidative stress, reactive metabolites, mitochondrial toxicity,
modulation of drug metabolizing transporters, induction of apop-
tosis or necrosis, as well as immunoallergic reactions to protein
adducts may all be involved in DILI, but for most of the drugs
the speciﬁc mechanisms contributing to DILI are unknown [2].
A classiﬁcation of hepatocellular, mixed or cholestatic liver injury
is used in the clinic to describe damage and severity of liver
injury but its value in predicting the outcome of DILI is unclear.
DILI can range from asymptomatic elevation of liver enzymes
to fulminant hepatic failure [1]. Its over-all mortality depends
on the drug used, the timely detection of DILI including the
appropriate action taken, as well as individual cofactors and
comorbidities such as the presence of diabetes mellitus [3]. Mor-
tality rates of approximately 10% [1] have been reported but may
be highly overestimated since most mild drug reactions will not
be registered. In most patients, DILI leads to a complete recovery.
However, up to 1% of all patients with DILI may develop liver cir-
rhosis subsequently [4].
DILI is a rare event with an estimated incidence of 1 per
10,000 to 1 per 100,000 treated patients [5]. Some risk factors
have been identiﬁed: the daily amount of the drug causing the
reaction (intake of >50 mg daily increases risk), a predominantly
hepatic metabolism of the drug (>50%) [6], and mitochondrial
dysfunction that may be the underlying cause of the increased
risk of DILI in diabetes patients [7]. Genetic polymorphisms
within genes relevant to drug metabolism [8] are being identiﬁed
and may be used to stratify the risk of DILI to certain drugs in the
future.
A question relevant to daily clinical practice is, if re-exposure
to the same or to other drugs may cause a second DILI episode.Journal of Hepatology 20
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(C. Schramm).Re-exposure to the same drug generally should be avoided due
to the considerable mortality rate reported after re-exposure to
drugs such as halothane (up to 50% due to a combination of mito-
chondrial and immune-mediated injury) [9]. Nonetheless, for
drugs that are urgently needed in case of life threatening disease,
such as in tuberculosis, careful re-exposure can be undertaken
after the resolution of the ﬁrst DILI episode with acceptable risk
[10]. The risk of re-exposure to a different drug that may belong
to the same class of drugs or be completely unrelated is not well
studied. To this end, the study presented by Lucena et al. in this
issue adds valuable and reassuring information [11]. In this study,
the Spanish DILI registry of patients with probable or highly
probable idiosyncratic DILI was searched for patients who suf-
fered from a second DILI episode. Only a small number of patients
(9 patients, 1.21%) from the cohort of patients with prior DILI
developed a second episode of liver injury and none of the
patients’ required liver transplantation or had a fatal outcome.
Of particular interest, the majority of patients (8 out of 9) expe-
riencing a second DILI episode had a similar (hepatocellular)
damage pattern. The drugs responsible for the second DILI epi-
sode were structurally related to the drug of the ﬁrst DILI episode
in 4 out of 9 cases and, in 2 cases, the target of the drug was the
same. This may point toward an immune-mediated drug injury
directed against similar protein adducts forming haptens. Indeed,
4 out of the 9 patients (44%) were diagnosed with so called ‘‘auto-
immune (AIH) DILI’’ since these patients fulﬁlled the criteria for
probable or deﬁnite AIH, according to the revised and simpliﬁed
score of the international autoimmune hepatitis study group
[12,13]. This number was considerably higher than in patients
with a ﬁrst DILI episode, where only 12/733 (1.6%) patients were
diagnosed with ‘‘AIH DILI’’ [11], suggesting that immune-medi-
ated reactions become the main mechanisms leading to DILI after
re-exposure to different drugs.
There is no consensus on the nomenclature of immune-med-
iated DILI and we will propose some deﬁnitions and respective
diagnoses at the end of this article. Until then, the diagnoses
given in the publications cited will be used.
In clinical practice, the differentiation between immune-med-
iated DILI and AIH may be challenging. There are no pathogno-
monic features of AIH and the diagnosis is made according to a
clinical, biochemical, serological, and histological pattern which
has to be conﬁrmed by the response to immunosuppressive treat-
ment [14]. This difﬁculty in differentiating between AIH and drug11 vol. 55 j 747–749
Table 1
DILI and AIH: suggested diagnoses and clinical characteristics.
Characteristics
AIH with DILI Patients with known AIH; probably chance association; often advanced fibrosis on histology 
Drug-induced AIH Patients with unrecognized AIH or predisposition to AIH, in whom AIH is unmasked or 
induced by DILI; good response to steroids; relapse after withdrawal of immunosuppression 
with the need for continued immunosuppressive treatment; chance association of drug intake 
in a patient with first presentation of AIH cannot be ruled out 
Immune-mediated DILI Clinical, biochemical, and histological signs similar to AIH; eosinophilia and rash may be 
present; usually no advanced fibrosis; good response to steroids; remission is maintained 
after successful withdrawal of steroids 
Editorialinduced immune-mediated liver injury has been recently high-
lighted by the study of Björnsson et al. [15] demonstrating that
in a large cohort of AIH patients, 9.2% suffered from ‘‘drug
induced AIH’’. There was no difference in histology or serological
ﬁndings and treatment response was similar between AIH cases
and ‘‘drug induced AIH’’. However, there were no relapses in
‘‘drug induced AIH’’ in those patients in whom immunosuppres-
sion was discontinued. This stands in contrast to the high relapse
rate after withdrawal of immunosuppression in AIH (65% in this
study), which in most cases remains a chronic disease [14]. Of
note, it has recently become clear that histological centrilobular
necrosis can be seen both in DILI as well as in acute AIH [15].
Likewise, auto-antibodies typically seen in AIH are sometimes
present in acute liver injury of varying causes and should, there-
fore, be interpreted with caution [16].
In the following, we would like to address various combina-
tions of DILI and AIH and to suggest appropriate diagnoses
(Table 1). There are several possible connections between DILI
and AIH.
The ﬁrst is that a patient with known AIH experiences DILI.
Whether this occurs more frequently than in other patients is
unknown. Liver histology will often reveal advanced ﬁbrosis in
these patients, which should be termed ‘‘AIH with DILI’’.
The second is that a patient has low grade AIH that has not
been diagnosed before or even just the predisposition to AIH that
is unmasked by DILI. The release of hepatic antigens and consec-
utive presentation of these autoantigens by immune cells may
lead to a continued – autoagressive – immune reaction in genet-
ically susceptible individuals. In a long term follow-up study of
685 patients with DILI and jaundice, from Sweden, 23 patients
had been hospitalized for liver disease and 5 of these were diag-
nosed with AIH after a mean of 5.8 years [4]. These mechanisms
may also be true for drugs interfering with cytokines such as anti-
TNFa [17] or b-Interferon [18]. In screening case reports and case
series, many of these patients developed ‘‘true’’ AIH with a per-
manent need for immunosuppression. Therefore, these patients
suffer from ‘‘drug-induced AIH’’. However, a chance association
of drug intake in a patient with previously unknown AIH cannot
be ruled out in these patients and in some, the symptoms of AIH
may even be the reason for taking the drug.
Thirdly, there are a number of drugs that are well known to
cause immune-mediated DILI. These are patients with hepatocel-
lular or mixed type of damage that do not improve after cessation
of the causative drug and frequently, but not always, present with748 Journal of Hepatology 201fever, eosinophilia, lymphadenopathy, and rash. These patients
may be indistinguishable from AIH by their clinical, laboratory,
and histological presentation and by their good response to
immunosuppressive treatment. In our experience, prominent
eosinophilic inﬁltrates may sometimes point toward DILI in these
cases. Among the drugs causing immune-mediated DILI are
antimicrobials such as nitrofurantoine and minocycline [15]. In
these patients, the early initiation of high dose steroid treatment
may be life saving. Of particular importance, unlike in true AIH,
most of these patients do not need permanent immunosuppres-
sion as they usually have sustained remission without relapse
after the initial treatment [15]. In line with this hypothesis,
HLA-associations have been identiﬁed for several antimicrobials
causing immune-mediated DILI, such as ﬂucloxacillin and
amoxicillin/clavulanate [19], which are unrelated to the HLA
haplotypes associated with AIH. Since these cases do not develop
AIH with a relapsing remitting course, we would suggest to call
these ‘‘immune-mediated DILI’’, and not to use the term
autoimmune.
So what do we learn for patient care? A second DILI involving
a different drug is a rare event but if it happens, immune-medi-
ated DILI is common. Differentiating immune-mediated DILI from
AIH is difﬁcult as the presentation may be the same. Liver histol-
ogy should be performed and eosinophilia may point toward DILI,
whereas centrilobular necrosis cannot be used to differentiate the
two. Prompt initiation of steroid treatment may be life saving in
both diseases. Most importantly, steroids should be withdrawn
once a complete biochemical remission has been achieved. This
may be the only way to discriminate between immune-mediated
DILI and true AIH, since the latter usually relapses and develops
into a chronic disease. More importantly, unnecessary long term
treatment can thus be avoided in most patients with immune-
mediated DILI.
Therefore, it seems important to differentiate between AIH
with DILI, drug induced AIH, and immune-mediated DILI (with
features of AIH) since long term treatment and prognosis may
signiﬁcantly differ.Conﬂict of interest
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